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pregnancy, ectopic pregnancy, suspension because bleeding and other causes, 
and other adverse events by using either LNG-IUS, etonogestrel Implants, 
levonorgestrel implants or copper T (last-two included in health care plan). 
Effectiveness, adverse events and adherence were taken from previously 
published studies and the costs were taken from database of patients in 
Colombia and are expressed in Colombian pesos (COP). An expert gynecologist 
reviewed data. Threshold was estimated in $6.823.583 by calculating the costs 
assigned by the public health care system in Colombia to health care during the 
first five years of life of children and cost of delivery care. A sensitivity analysis 
was developed using a Montecarlo simulation and a Tornado analysis. RESULTS: 
TOTAL OF 13.87 pregnancies occurred with using LNG-IUS as compared with 
40.39 using Copper T, 30.08 using etonorgestrel implant, and 29.55 using 
levonorgestrel implant for the base case analyzed. Cost of LNG-IUS arm was 
COP$ 633,747,545 compared with copper T (COP$ 456,638,680), the less expensive. 
Applying a discount rate of 3% LNG-SIU was dominant versus implant 
etonogestrel and very cost-effective compared with levonorgestrel implant (ICER 
$631,682.98) and cost-effective compared with Copper T (ICER COP$ 6,678,395.53). 
Sensitivity analyses confirm that LNG-UIS keeps its benefits against etonogestrel 
and levonorgestrel in most cases. CONCLUSIONS: The use of LNG-IUS would be 
an adequate option for patients seeking a long-acting contraceptive method and 




COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS 
INFECTION (RSV) WITH PALIVIZUMAB IN PRETERM INFANTS IN COLOMBIA  
Rosselli D, Rueda JD, Ruiz JG 
Pontificia Universidad Javeriana, Bogota, Colombia  
OBJECTIVES: Infection due to respiratory syncytial virus (RSV) is usually 
transient and leaves no sequelae; however, in infants with risk factors such as 
prematurity, bronchopulmonary dysplasia, congenital heart disease or 
infections, it can be more severe, and imply higher costs. Some observational 
studies support the likelihood of an association between RSV and asthma. 
According to the Colombian Medical Federation, palivizumab was one of the ten 
most expensive drugs for the Colombian health system (US$43.6 million in the 4-
year period 2008-11). The aim of this study was to evaluate the cost-effectiveness 
of palivizumab for the treatment of RSV infections in pre-term (<35 weeks) 
infants in Colombia. METHODS: We designed a decision tree model using local 
epidemiological data, effectiveness and safety, as well as QALYs, obtained from 
the scientific literature. We used the third-party payer perspective and a 3% 
discount rate for costs and long term outcomes. The time horizon was the 
lifetime of the patient. RESULTS: In our base case model, compared with no 
prophylaxis palivizumab showed on average an increase in costs per child of 
US$4.895, with 0.1645 QALYs gained, resulting in an incremental cost-
effectiveness ratio of US$29.760 per QALY (our per capita GDP is US$6723). Other 
outcomes of importance in the model were: US$359.962 per asthma case averted, 
US$1.087.884 per life saved and US$75.084 per hospitalization averted. The price 
of paliviumab should be decreased 32% to reach the cost-effectiveness threshold 
of 3-times the per capita GDP. CONCLUSIONS: Under the assumptions and 
results of our study, palivizumab is not a cost-effective intervention and should 
not be recommended for routine immunization in preterm infants of 35 weeks 




COST MINIMIZATION COMPARISON OF DARUNAVIR + RITONAVIR (DRV+RTV) 
TO LOPINAVIR/RITONAVIR (LPV/R) IN HIV-1 INFECTED TREATMENT-NAÏVE 
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OBJECTIVES: HIV guidelines consider LPV/r a preferred protease inhibitor for use 
during pregnancy. The budget implications of proactively initiating LPV/r versus 
initiating DRV+RTV and then potentially switching to LPV/r upon pregnancy 
were examined. METHODS: A cost minimization analysis was performed (US 
health care perspective) for HIV-1 infected, treatment-naïve WOCBA comparing: 
initiating LPV/r versus initiating DRV+RTV and switching to LPV/r when 
pregnant. A discrete event simulation was employed to represent antiretroviral 
(ARV) therapy management. Clinical trial data were used to model pregnancy 
rates, ARV switch rates, treatment impact as a function of CD4-cell count/viral 
load, adherence, treatment response, acquired resistance mutations, and 
treatment changes. Five- and 10-year costs incurred due to ARV therapy, clinical 
management of AIDS-related, non-AIDS related, and cardiovascular events were 
estimated. Analysis assumptions: switching to LPV/r can occur only once at first 
pregnancy, women’s medication adherence improves 15% at pregnancy and to 
100% if viral rebound. Analyses varied the rate of switching to LPV/r at time of 
pregnancy (0%, 30%, 100%), pregnancy rates, adherence improvement, and 
health care costs. Daily drug cost (WAC): LPV/r + TDF/FTC, $56.59; 
DRV+RTV+TDF/FTC, $73.89. Costs were discounted 3% per annum. RESULTS: 
With 0% switch, survival was similar for LPV/r and DRV+RTV, 7.68 and 7.69 life 
years, respectively (+/- 0.03 QALYs) at 10 years. Five- and 10-year health care 
costs of ARV-naïve WOCBA who initiate LPV/r were $107,790 and $192,352 per 
patient, respectively, versus $132,694 and $235,854 when initiating DRV+RTV (a 
$43,502 per patient savings at 10 years). If 100% of patients who initiated 
DRV+RTV switched to LPV/r upon pregnancy, savings per patient were reduced 
21.3%. Sensitivity analyses showed that initiating LPV/r was always cost-saving 
relative to DRV+RTV. CONCLUSIONS: Initiating HIV infected, treatment-naïve 
WOCBA on LPV/r was cost saving compared to initiating DRV+RTV. Analysis 
limitations include the uncertainty of long-term outcomes projections driven by 
short-term clinical trial endpoints.  
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OBJECTIVES: Labor induction has increasingly been used in the management of 
obstetrical care, owed to post-term pregnancies, maternal/fetal complications 
and voluntary election. Several cervical ripening and induction agents are 
available, though failure or complications with administration of current agents 
are common. Induction failure generally necessitates either additional induction 
agents and/or an eventual cesarean section. This analysis descriptively 
quantifies the economic burden associated with failed medical inductions 
among US Commercial and Medicaid patients. METHODS: A retrospective 
analysis of inpatient hospital discharge data for 2010, using the Healthcare Cost 
and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) was 
performed, to identify delivery stays with primary or secondary diagnoses of 
failed medical induction (ICD9 659.10-659.13). Rates of cesarean and vaginal 
delivery, average medical charges (converted to costs and displayed in 2010 USD) 
and length of stay per patient are provided. RESULTS: Failed labor induction 
discharges totaled 41,600 in 2010. The average cost for a vaginal delivery (with or 
without complications) after failed induction was $5,890 (average charges of 
$17,645) this is compared to average cost of $3,860 (average charges of $10,106) 
for all vaginal deliveries. Hospital cost for cesareans after failed induction 
averaged $7,595 (average charges of $28,700) compared to $5,990 (average 
charges of $21,875) for all cesarean sections. Average length of stay for failed 
induction with cesarean was 4.42, compared to 3.8 days with vaginal deliveries 
post-induction failure. CONCLUSIONS: Failed medical induction is associated 
with increased risk of cesarean delivery, and associated increased hospital 
resource use, and expenditure in delivery. Preventing complications with 
induction may substantially reduce health care costs and resource utilization.  
 




VARIATION IN COST-RELATED MEDICATION NON-COMPLIANCE WITH 
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OBJECTIVES: Cost-related medication non-compliance (CRN) is a persistent issue 
that negatively impacts the effectiveness of medical intervention. This study 
aims to evaluate the variation of CRN with functional deficiencies and with 
frequency of hospitalization among the US elderly using a nationally 
representative data set. METHODS: Health Retirement Survey (HRS) 2010 was 
used to assess CRN, deficiencies in Activities of Daily Living (ADL), Instrumental 
Activities of Daily Life (IADL), and frequency of hospitalization over the past 2 
years (0, 1, 2, 3, or 4 or more). CRN was assessed based upon self-reported non-
compliance. After performing bivariate analyses of the association between 
ADLs/IADLs, hospitalizations, insurance coverage, self-reported monthly out-of-
pocket (OOP) payments of prescription drugs and CRN, a logit model was used to 
assess the relationship between CRN and associated risk factors. RESULTS: 2,793 
(12.7%) out of 22,042 elderly reported CRN over a period of 2 years. Those 
reported CRN has a mean ADL deficiencies 0.79 (s.d. 1.43) versus those who did 
not 0.48 (s.d. 1.16) (p<0.001), and a mean IADL deficiencies 0.53 (s.d. 0.97) versus 
those who did not 0.38 (s.d. 0.92) (p<0.001). The logit model showed that 
compared to those who did not have hospitalization, those who had 1 admission 
were 17% more likely to report CRN (p=0.005), those with 2 admissions 14% more 
likely (p=0.10), 3 admissions 54% more likely (p<0.001), and 4 or more admissions 
33% more likely to report CRN (p=0.007). There was an inverse U-shaped 
relationship between CRN and deficiencies in ADLs/IADLs; as ADL/IADL 
deficiencies increased, the likelihood of CRN first increased and then decreased. 
CONCLUSIONS: The positive relationship between number of hospitalization and 
CRN and the inverse U-shaped relationship between functional deficiencies and 
CRN raise concerns that CRN may decrease the effectiveness and increase the 
cost of care in this population.  
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OBJECTIVES: The Women’s Health Initiative (WHI) estrogen+progestin (E+P) 
clinical trial provides a large sample to estimate health state utility values for 
post-menopausal women with an intact uterus in the United States. To facilitate 
future health economic evaluations in this large population sub-group, we 
estimated utilities for trial participants stratified by age group (50-59, 60-69, 70-
79) and randomization assignment (E+P or placebo). METHODS: We measured 
health state utility values for all 16,608 trial participants with the Short Form-6D 
(SF-6D) utility index using a validated Bayesian mapping algorithm and U.S. 
weights. We calculated cross-sectional mean baseline and 1-year utilities, and 
mean within-patient utility change from baseline to 1-year. Patients included in 
the baseline analysis completed the SF-36 within 7 days of randomization, and 
A76 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
those included in the 1-year and change analyses completed the SF-36 within 30-
days of their 1-year follow-up date. RESULTS: All patients contributed to the 
baseline analysis, and approximately 47% contributed to the 1-year and change 
analyses. At baseline, mean SF-6D values for all patients 50-59, 60-69, and 70-79 
were 0.744 (SD=0.113), 0.743 (SD=0.105), and 0.722 (SD=0.101), respectively. At 1-
year, E+P arm mean values were 0.754 (SD=0.117), 0.751 (SD=0.117), and 0.725 
(SD=0.109), and placebo arm mean values were 0.751 (SD=0.122), 0.748 (SD=0.109), 
and 0.716 (SD=0.106), respectively. The E+P arm mean changes were -0.008 
(SD=0.106), -0.004 (SD=0.096), and 0.000 (SD=0.093), and the placebo arm mean 
changes were 0.000 (SD=0.105), -0.003 (SD=0.095), and 0.011 (SD=0.093), 
respectively. CONCLUSIONS: We found minimally decreasing utilities among 
older age groups, and little variability between utilities by hormone replacement 
therapy use. These results may be particularly useful in future health economic 
evaluations of aging women given that they are derived from a large randomized 
sample, and age group specific. However, our findings may be limited by the 
homogeneity and representativeness of the E+P trial participants.  
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OBJECTIVES: National health care policy in Brazil is delivered via a two-tiered 
(public/private) system. Controversy exists since access to private insurance is 
skewed towards those with higher socioeconomic status, with 75% having 
incomes >5x the minimum wage, and 95% living in urban areas, mainly in the 
South and Southeast regions. Our objective was to assess the impact on health 
status, productivity and health care utilization due to insurance type among 
patients residing in different regions of Brazil. METHODS: Data were analyzed 
from the 2011 National Health and Wellness Survey, a nation-wide survey of 
adults in Brazil (N=12,000). Health status (SF-12v2), work productivity loss 
(WPAI), and health care resource use within a six-month time frame were 
compared across individuals in different insurance type strata (i.e., 
public/private). Data were also stratified according to Brazilian regions 
comprising the Mid-West, North, Northeast, South and Southeast, and the 
Federal District. Statistics included unpaired Student-t and Chi-square tests. 
ANOVA was used to test differences among regions of Brazil. RESULTS: A total 
11,985 individuals comprised the public (N=6,074) and private (N=5,911) 
insurance assessment. Health care utilization was significantly lower among 
individuals with private insurance (physician consultations: 70.9% versus 86.0%; 
emergency room visits: 19.6% versus 25.7%; and hospitalizations: 8.9% versus 
11.0%; all p<0.05). Overall work impairment (i.e., absenteeism and presenteeism 
combined) was also significantly lower in the private insurance group 
(difference=2.8%, 95%CI=1.3%-4.3%). Mental SF-12 score favored those with 
private insurance (difference=0.058, 95%CI=0.022-0.095), whereas physical SF-12 
score favored those with the public insurance (difference=0.062, 95%CI=0.035-
0.088). Mid-West and Northern regions reported significantly poorer results than 
the Southern in almost all assessed parameters. CONCLUSIONS: Individuals 
covered with private insurance reported both lower health care utilization and 
work productivity loss. Variable results were reported for health status. Future 
research should examine the relationship in access/quality between public and 
private health care services and regions in Brazil.  
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OBJECTIVES: Hemophilia is a bleeding disorder resulting from reduced or absent 
clotting factors. Inhibitors are alloantibodies that develop in response to 
replacement therapy with coagulation factor products. Patients are diagnosed at 
birth or shortly thereafter, and care is typically provided at home by parents and 
relatives (i.e., caregivers). Few formal studies have explored the experience of 
caregivers of children with hemophilia. This study aimed to quantify the overall 
burden of hemophilia on caregivers using a novel questionnaire. METHODS: A 
questionnaire with six domains (emotional stress, financial, sacrifice, medical 
management, child’s pain, and transportation) and several visual analogue 
scales (VAS) was developed based upon the peer-reviewed literature and 
previous survey findings. Survey questions were validated with 3 caregivers. 
Previously developed opt-in research database was used for recruitment. IRB 
approval was obtained. RESULTS: A total of 310 caregivers (out of 681 invitees) 
completed the survey. Most respondents were mothers (88%) between 18-54 
years. 89% had at least some college education. “Child’s pain” was the most 
burdensome domain (mean score=3.54 out of 5), followed by “emotional stress” 
(2.79), “financial” (2.52), “transportation” (2.51), “sacrifice” (2.22) and “medical 
management” (2.05). Caregivers of inhibitor patients had higher total burden 
scores (96.17 vs. 78.65, p<0.0001) and burden VAS scores (5.57 vs. 3.44, p<0.0001) 
compared to those without inhibitors. Similar trends were seen for those 
diagnosed with hemophilia ≤2 years ago versus all else (86.36 vs. 79.83,  
p<0.04; burden VAS 4.89 vs. 3.47, p<0.0002). Other factors significantly impacting 
burden were: income ≤ $50,000, taking ≥ 6 hours off work or having >1 bleed in 
past month (p<0.001). CONCLUSIONS: Hemophilia caregivers are largely 
impacted by the burden of their child’s pain and emotional stress. Since 
caregivers of patients with inhibitors and those with ≤2 years since diagnosis 
were more significantly burdened, potential programs can be developed to 
lessen their burden.  
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OBJECTIVES: Improved satisfaction with facial appearance is the primary desired 
outcome for patients undergoing facelift procedures. The FACE-Q is a new 
patient-reported outcome (PRO) instrument composed of scales to evaluate  
a range of outcomes (appearance concerns, quality of life, adverse effects)  
for patients undergoing any type of facial cosmetic surgery, minimally invasive 
cosmetic procedure or facial injectable. The objective of this study was  
to describe the development and psychometric properties of a set of FACE- 
Q scales relevant to measuring outcomes in facelift patients. METHODS:  
The FACE-Q was developed according to international guidelines for PRO 
instrument development. Scales relevant to facelift patients include five 
appearance scales (each with five items) covering the following facial areas: 
cheeks, lower face and jawline, nasolabial folds, area under the chin, and neck. 
In addition, an adverse effects checklist was developed to measure postoperative 
symptoms and complications. Data were collected in a larger study that included 
225 facelift patients (all had surgery within the past 5 years) between June 2010 
and June 2012 (response rate 78%). Rasch measurement theory (RMT) analyses 
was used to examine clinical meaning, thresholds for item responses, item fit, 
item locations, differential item functioning (DIF), standardized residuals, and 
person separation index (PSI). RESULTS: Participants were aged 36 to 77 years 
and 205 were female. The five appearance scales were found to be clinically 
meaningful, reliable, valid and responsive to clinical change. Specifically, RMT 
findings were as follows: no disordered thresholds; overall and individual item 
fit statistics (29/30 items -2.5/+2.5); no DIF by gender, age or ethnicity; PSI > 0.88 
(0.88-0.90). Cronbach’s alpha were all >0.94 (0.94-0.97). CONCLUSIONS: The FACE-
Q scales for facelift patients are scientifically sound and clinically meaningful 
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OBJECTIVES: To use the Theory of Planned Behavior (TPB) to predict university 
students’ intention to use emergency contraception (EC). METHODS: A web-
based survey was pretested and emailed to 2,000 university students in May 
2010. The web-based survey measured the essential components of the Theory 
of Planned Behavior: intention, attitude (A), subjective norm (SN), and perceived 
behavioral control (PBC). The independent variables, A, SN, and PBC, were 
measured directly as well as by belief-based (indirect) measures. In addition, a 
measure of recent past behavior was evaluated. RESULTS: An overall usable 
response rate of 21.0% was obtained. In general, university students intended to 
use EC should the need occur, held favorable attitudes toward the use of EC, 
were somewhat influenced by social norms regarding EC use, and perceived 
themselves to have some control over EC utilization. For direct measures (TPB), 
A, SN, and PBC were significant predictors of intention to use EC. The direct 
model explained 49.2 percent of the variance in intention. Using indirect 
measures, A and SN were significant predictors of intention, but PBC was not; 
the indirect model accounted for 41.3% of the variance in intention to take EC. 
Attitude was the strongest TPB predictor for both models, followed by SN and 
PBC. The RPB variable did not significantly improve the TPB model. 
CONCLUSIONS: In summary, this study identified several key factors that 
partially explain why university students either intend or do not intend to use EC 
if needed. The TPB has utility in predicting utilization of EC in university 
students. Focusing particular attention on A, as well as SN and PBC, will allow 
researchers, educators, health care professionals, and legislators to develop 
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OBJECTIVES: To demonstrate how patient interviews reinforce a conceptual 
model of endometriosis symptoms and impact and help to identify concepts for 
inclusion in an improved Endometriosis Pain Daily Diary (EPDD). METHODS: 
Concept elicitation (CE) interviews were conducted with 17 surgically diagnosed 
endometriosis patients in the US to identify the PRO measurement concepts 
related to symptoms and impacts of endometriosis-related pain most important 
and relevant to patients’ experience of endometriosis. Items were developed 
based on the Endometriosis Pain and Bleeding Diary (EPBD) and existing 
conceptual data. Cognitive interviews (CI) were conducted with 14 patients in the 
US to confirm comprehension of the draft items and ability to respond to the 
items as intended. RESULTS: Based on both spontaneous mentions and the 
frequency with which concepts were expressed during the CE interviews, 
